查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1854168

细胞免疫疗法市场按类型、技术类型、适应症和设施类别划分 - 全球预测 2025-2032

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞免疫疗法市场规模将达到 301.8 亿美元，复合年增长率为 12.34%。

关键市场统计数据
基准年2024年 118.9亿美元
预计年份：2025年 132.9亿美元
预测年份 2032 301.8亿美元
复合年增长率 (%) 12.34%

本书重点介绍塑造现代细胞免疫疗法的科学创新、临床需求和操作复杂性之间的整合。

细胞免疫疗法已进入科学、临床和商业策略整合的阶段，这为价值链上的相关人员带来了独特的机会和营运挑战。工程化细胞平台的最新进展，以及生产和监管途径的不断改进，正在扩大可能的治疗方法范围。同时，人们对安全性、疗效持久性和成本效益的日益增长的期望，正在改变研发人员、临床中心和合约合作伙伴对投资和规模化生产的优先排序。

因此，决策者必须权衡临床前景与物流的现实。转化医学的进步正在加速候选化合物从早期发现到关键性试验的进程，但这一进程需要强大的供应链、品管系统和战略伙伴关係关係，以确保结果的可重复性。同样重要的是，支付方和医疗服务提供者正在仔细审查循证策略和实际应用效果，以支持报销和医疗服务可近性。在此背景下，本书以清晰观点的导论开篇，揭示了技术演进与实际应用之间的相互关係，为深入分析后续的市场变化、政策阻力和组织需求奠定了基础。

分析技术多元化、营运规模和伙伴关係模式如何重塑细胞治疗领域的转化路径和商业性准备。

在技​​术突破和相关人员不断变化的期望的双重推动下，变革性转变正在重塑细胞免疫疗法的多个方面。治疗方法正从第一代过继性细胞疗法发展到更复杂的工程方法、改进的安全开关以及将细胞药物与标靶生技药品结合的混合平台。这种多样化促使申办方重新评估研发路径，以平衡差异化疗效的潜力与日益复杂的生产製造和法律规范。

同时，製造业正从客製化的集中式生产转向更标准化、模组化和可扩展的流程。自动化、封闭式系统工作流程和品质源自于设计 (QbD) 方法的进步，在提高产量的同时，也力求降低批次差异。这些营运方面的改进，与日益重视分散式临床网路以及生物技术公司、临床机构和专业合约组织之间的策略联盟相辅相成。因此，伙伴关係正从交易型供应商关係演变为以共同开发、风险共用和产能协调为重点的整合式合作。总而言之，这些转变正在加速临床试验的进程，同时也提升了严格的流程控制和相关人员之间策略合作的重要性。

对关税上调动态将如何影响细胞治疗价值链的供应链生产连续性和专案进度进行策略性评估

新关税和贸易措施的实施给细胞免疫疗法计画带来了巨大的营运压力，尤其是在关键投入品跨境供应或专用设备供应商有限的情况下。关税导致的试剂、一次性耗材和精密仪器的成本上涨，会立即造成采购压力，迫使企业重新评估筹资策略和库存政策。实际上，这通常意味着更长的前置作业时间、更高的营运成本需求，以及检验替代供应商以避免临床和生产活动中断的必要性。

除了直接的成本影响外，关税还可能透过降低全球零件流动的弹性，并鼓励近岸外包和区域回流，从而加剧供应链的脆弱性。先前依赖国际供应商网路的公司可能面临供应商合约重新谈判和设备部署延迟，这可能会影响试验註册时间表和生产规模扩大计画。为了降低这些风险，许多公司正在评估本地供应商发展、多元化采购策略和策略性库存缓衝，同时加强与监管机构的对话，探讨替代材料的可接受等效性和合格途径。

重要的是，关税压力的累积影响往往在整个价值链中分布不均。规模较小的生物技术研发公司和采购受限的学术中心可能承受不成比例的营运负担，而拥有多元化供应链和内部生产能力的大型机构可能更能抵御短期衝击。然而，长期的关税环境可能会改变投资重点，加速供应链关係的整合，并在监管和经济状况允许的情况下，奖励国内生产能力的建设。因此，相关人员应将关税情境规划纳入其临床开发和商业化蓝图，以维持专案的连续性和策略灵活性。

基于细分视角的深入观点，将治疗方式与辅助技术、适应症和设施能力相匹配，从而设计出切实可行的策略。

細項分析对于明确研发策略与患者群体、生产路径和组织能力之间的匹配至关重要。按类型划分，包括 CAR-T 细胞疗法、树突细胞疗法、NK 细胞疗法、T 细胞受体疗法和肿瘤浸润淋巴细胞疗法，每种疗法都有不同的研发週期、安全性特征和生产需求。例如，工程化 CAR-T 构建体需要先进的病毒载体生产流程和严格的效力检测，而 NK 细胞疗法可能更侧重于扩增方案和现成的物流。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • CAR-T细胞疗法的临床应用日益广泛
  • 扩展照护现场自动化细胞处理平台，以简化治疗工作流程
  • 不断完善的法规结构加速了下一代基因编辑细胞免疫疗法的核准
  • 人工智慧与巨量资料分析的融合将优化个人化细胞疗法的生产过程。
  • 将CAR-T细胞疗法与查核点抑制剂结合的联合治疗正在兴起，以提高难治性癌症的疗效。
  • 提高细胞製造效率的技术进步
  • 基于 CRISPR 的 CAR-T 细胞设计技术的进步推动了下一代免疫疗法的发展。
  • 生物技术製药策略联盟推动细胞疗法生产快速扩张
  • 新的研究重点是固态肿瘤的免疫疗法策略
  • 常规生物反应器的创新提高了下一代细胞疗法的可扩展生产能力。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 细胞免疫疗法市场（按类型划分）

  • CAR-T细胞疗法
  • 树突细胞疗法
  • NK细胞疗法
  • T细胞受体治疗
  • 肿瘤浸润淋巴细胞治疗

9. 依技术类型分類的细胞免疫疗法市场

  • 细胞激素和免疫调节剂
  • 单株抗体

第十章 依适应症分類的细胞免疫疗法市场

  • B细胞恶性肿瘤
  • 肝癌
  • 摄护腺癌
  • 肾臟细胞癌

第十一章 依机构类别分類的细胞免疫疗法市场

  • 学术机构
  • 生物技术和製药公司
  • 合约组织
  • 医院
  • 研究机构

第十二章 各地区细胞免疫疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 细胞免疫疗法市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国细胞免疫疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Adaptimmune Therapeutics PLC
    • Adicet Bio, Inc.
    • Apac Biotech Private Limited
    • AstraZeneca PLC
    • Atara Biotherapeutics, Inc.
    • Bellicum Phamaceuticals, Inc.
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • Celyad Oncology SA
    • Corning Incorporated
    • Dendreon Pharmaceuticals LLC
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Glycostem Therapeutics BV
    • Immatics NV
    • Inovio Pharmaceuticals, Inc.
    • Iovance Biotherapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • Lonza Group Ltd.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market is projected to grow by USD 30.18 billion at a CAGR of 12.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.89 billion
Estimated Year [2025] USD 13.29 billion
Forecast Year [2032] USD 30.18 billion
CAGR (%) 12.34%

A focused introduction that frames the convergence of scientific innovation clinical demands and operational complexities shaping modern cellular immunotherapy

The cellular immunotherapy landscape has entered a phase where science, clinical practice, and commercial strategy converge to create distinct opportunities and operational challenges for stakeholders across the value chain. Recent advances in engineered cell platforms, coupled with iterative improvements in manufacturing and regulatory pathways, have expanded the scope of adoptable therapeutic approaches. At the same time, rising expectations around safety, durability of response, and cost-effectiveness are reshaping how developers, clinical centers, and contract partners prioritize investment and scale-up.

As a result, decision-makers must reconcile clinical promise with logistical realities. Translational progress has accelerated candidate pipelines from early discovery into pivotal studies, but this trajectory demands robust supply chains, quality management systems, and strategic partnerships to ensure reproducible outcomes. Equally important, payers and providers are scrutinizing evidence generation strategies and real-world performance to support reimbursement and access. In this context, a clear-eyed introduction clarifies the interplay between technological evolution and practical implementation, setting the stage for deeper analysis of market shifts, policy headwinds, and organizational imperatives that follow.

An analysis of how technological diversification operational scale and partnership models are reshaping translational pathways and commercial readiness in cell therapy

Transformative shifts are redefining cellular immunotherapy across multiple dimensions, and these changes are driven by both technological breakthroughs and evolving stakeholder expectations. Therapeutic modalities are diversifying beyond first-generation adoptive cell therapies to include more refined engineering approaches, improved safety switches, and hybrid platforms that combine cellular agents with targeted biologics. This diversification is prompting re-evaluation of development paths, as sponsors balance the potential for differentiated efficacy against increased complexity in manufacturing and regulatory oversight.

Concurrently, manufacturing is transitioning from bespoke, center-based production toward more standardized, modular, and scalable processes. Advances in automation, closed-system workflows, and quality-by-design approaches are enabling higher throughput while aiming to reduce batch variability. These operational improvements are complemented by a growing emphasis on decentralized clinical networks and strategic alliances between biotechnology companies, clinical institutions, and specialized contract organizations. Accordingly, partnerships are evolving from transactional vendor relationships into integrated collaborations focused on co-development, shared risk, and capacity alignment. Taken together, these shifts are accelerating clinical translation while simultaneously elevating the importance of rigorous process control and strategic alignment among stakeholders.

A strategic assessment of how elevated tariff dynamics influence supply chains manufacturing continuity and program timelines across the cell therapy value chain

The introduction of new tariffs and trade measures presents a material operational stressor for cellular immunotherapy programs, particularly where key inputs cross borders or where specialized equipment originates from a narrow set of suppliers. Tariff-driven cost increases on reagents, single-use consumables, and precision instruments can create immediate procurement pressure, prompting organizations to reassess sourcing strategies and inventory policies. In practice, this often translates into longer lead times, elevated working capital requirements, and the need to validate alternative suppliers to maintain uninterrupted clinical and manufacturing activities.

Beyond direct cost impacts, tariffs can amplify supply chain fragility by reducing the resilience of global component flows and incentivizing nearshoring or regional reshoring initiatives. Companies that previously relied on international vendor networks may encounter renegotiation of supplier contracts or delays in equipment deployment, which in turn can affect study enrollment timelines and manufacturing scale-up plans. To mitigate these risks, many organizations are evaluating localized supplier development, multi-sourcing strategies, and strategic inventory buffers, while also escalating dialogue with regulatory bodies about acceptable equivalence and qualification pathways for alternate materials.

Importantly, the cumulative effect of tariff pressures is often felt unevenly across the value chain. Smaller biotech developers and academic centers with constrained procurement leverage may experience disproportionate operational strain, whereas larger organizations with diversified supply bases and in-house manufacturing capabilities might better absorb short-term shocks. However, prolonged tariff environments have the potential to redirect investment priorities, accelerate consolidation of supply relationships, and incentivize the development of domestic manufacturing capacity where regulatory and economic conditions permit. Stakeholders should therefore integrate tariff scenario planning into clinical development and commercialization roadmaps to maintain program continuity and strategic flexibility.

Insightful segmentation-driven perspectives that align therapy modalities adjunct technologies indications and institutional capabilities for actionable strategy design

Segmentation analysis offers critical clarity when aligning development strategies to patient populations, manufacturing pathways, and institutional capabilities. Based on Type, the landscape encompasses CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, T-Cell Receptor Therapy, and Tumor-Infiltrating Lymphocytes Therapy, each presenting distinct development timelines, safety profiles, and manufacturing needs. For example, engineered CAR T constructs demand sophisticated viral vector production and stringent potency assays, whereas NK cell approaches may emphasize expansion protocols and off-the-shelf logistics.

Based on Technology Type, the field differentiates between Cytokines & Immunomodulators and Monoclonal Antibodies, which interact with cellular therapies in combinatorial regimens and supportive care strategies. These adjunct technologies shape clinical trial design, biomarker strategies, and dosing paradigms, influencing both efficacy benchmarks and regulatory expectations. Based on Indication, the therapeutic focus spans B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma, each indication requiring tailored clinical endpoints, patient selection criteria, and evidence-generation approaches to demonstrate meaningful benefit.

Based on Institution Category, the ecosystem includes Academic Institutes, Biotech & Pharmaceutical Companies, Contract Organizations, Hospitals, and Research Institutes, with each actor contributing unique capabilities. Academic institutes often lead early translational research and investigator-initiated trials; biotech and pharmaceutical companies drive clinical development and commercialization strategy; contract organizations deliver scale-up and manufacturing services; hospitals provide clinical trial sites and real-world data capture; and research institutes contribute foundational science and biomarker discovery. Recognizing how these segments intersect helps stakeholders prioritize investments, select partners, and design clinical programs that reflect therapeutic modality, technological adjuncts, target indications, and institutional strengths.

Comparative regional perspectives on regulatory readiness commercial access and infrastructure scale that determine adoption pathways across global markets

Regional dynamics fundamentally affect development strategies, regulatory pathways, and commercial access for cellular immunotherapies. In the Americas, infrastructure depth, payer engagement models, and clinical trial networks support rapid patient accrual and iterative evidence generation, while commercialization requires close coordination with reimbursement stakeholders to demonstrate value and long-term outcomes. Regulatory frameworks in this region increasingly accommodate advanced therapies through expedited pathways, yet manufacturers must still navigate complex manufacturing compliance and post-approval evidence commitments.

Across Europe, Middle East & Africa, regulatory plurality and diverse healthcare financing structures create both opportunities and challenges. Certain European jurisdictions offer innovative reimbursement mechanisms for high-cost therapies, but broader market access often requires adaptive evidence strategies and region-specific health economic modeling. In some Middle Eastern and African markets, the emphasis rests on capacity building, infrastructure development, and clinician training to support safe and effective administration of cellular therapies.

The Asia-Pacific region is characterized by heterogeneity in regulatory maturity, manufacturing capacity, and clinical adoption rates. Some markets in the region are rapidly expanding local production capabilities and investing in clinical trial infrastructure, while others focus on strategic collaborations with global sponsors to access novel therapies. Across all regions, cross-border collaborations, regulatory harmonization efforts, and investments in workforce and facility readiness will be decisive factors shaping the pace at which these therapies move from clinical proof-of-concept to routine clinical practice.

Strategic company-level observations showing how integrated clinical pipelines manufacturing capabilities and IP strategies drive competitive advantage and partnership leverage

Competitive dynamics in cellular immunotherapy are shaped by a combination of clinical pipelines, manufacturing footprints, intellectual property strategies, and strategic alliances. Leading organizations emphasize an integrated approach that aligns robust clinical development with scalable manufacturing capabilities and comprehensive quality systems. Investment in closed-system manufacturing, automation, and supply chain traceability emerges as a common priority, as firms seek to reduce variability and accelerate batch release timelines.

Strategic collaborations between developers and specialized contract organizations are becoming more sophisticated, with partners co-designing manufacturing processes, sharing validation data, and coordinating regulatory submissions. Companies that prioritize platform extensibility, regulatory engagement, and real-world evidence generation typically preserve optionality across indications and combinations. Intellectual property stewardship also plays a critical role; organizations with clear freedom-to-operate and strong patent portfolios tend to command greater negotiating leverage when forming licensing deals or co-development partnerships.

Finally, corporate strategies increasingly recognize the importance of integrated commercial planning. Cross-functional alignment between clinical development, regulatory affairs, manufacturing, and market access teams underpins successful launches. Firms that proactively model provider workflows, reimbursement pathways, and long-term safety monitoring requirements position themselves to convert clinical success into sustainable clinical adoption and payer acceptance.

Actionable recommendations for executives to strengthen manufacturing resilience align evidence generation with access needs and secure strategic partnerships for durable commercialization

Industry leaders must act decisively to convert scientific progress into durable clinical and commercial outcomes. First, prioritize modular and scalable manufacturing investments that support platform consistency across indications, while incorporating automation and quality-by-design principles to reduce batch variability. This investment should be paired with supplier diversification and regional sourcing strategies to mitigate trade and tariff disruptions. Second, adopt a partnerships mindset that moves beyond transactional relationships to form co-development arrangements with contract organizations, hospitals, and research institutes, aligning incentives around capacity, data sharing, and mutual regulatory goals.

Third, integrate evidence generation across clinical and real-world settings by designing trials with pragmatic endpoints and post-approval registries that address payer and provider requirements. Early engagement with reimbursement authorities and HTA bodies will streamline pathways to access and inform commercial pricing strategies. Fourth, strengthen talent pipelines and operational governance by investing in cross-functional teams that bridge clinical, manufacturing, quality, and commercial expertise, ensuring rapid decision-making during scale-up and launch phases.

Finally, build strategic resilience through scenario planning that encompasses trade policy changes, supply chain disruptions, and shifts in reimbursement. By simulating alternative procurement and clinical deployment pathways, leaders can reduce time-to-resolution for operational contingencies and preserve momentum across development milestones. Collectively, these actions help organizations translate innovation into reliable patient access and sustainable business models.

A transparent and multi-method research approach combining primary stakeholder engagement secondary evidence synthesis and expert validation to ensure actionable insights

The research methodology driving this analysis combined rigorous qualitative and quantitative approaches to ensure robust and validated insights. Primary research consisted of structured interviews and in-depth discussions with stakeholders across the ecosystem, including clinical investigators, manufacturing leaders, regulatory experts, and commercial strategists. These engagements captured operational realities, strategic priorities, and experiential learnings that underpin practical recommendations.

Secondary research included a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trends, clinical endpoints, and regulatory milestones. Data triangulation was employed to reconcile divergent perspectives and to validate assertions across sources. An iterative synthesis process integrated thematic analysis with scenario planning to surface material risks and strategic opportunities.

Quality assurance measures involved expert panel reviews and internal validation checks to confirm factual accuracy and relevance. Where appropriate, methodological caveats and confidence qualifiers were noted to indicate areas where evidence remains emergent or where industry practice is still evolving. This combined approach ensures that the conclusions and recommendations are grounded in contemporary practice and reflect the operational complexity inherent to cellular immunotherapy development and deployment.

A concise synthesis underscoring the critical alignment of technical innovation operational preparedness and strategic foresight required to realize cell therapy potential

In conclusion, cellular immunotherapy stands at an inflection point where scientific sophistication and operational readiness must align to fulfill therapeutic promise. Technological diversification is expanding clinical possibilities, yet it concurrently raises demands for manufacturing precision, supply chain robustness, and strategic partnership models that can support scale and consistent patient outcomes. Policy and trade dynamics introduce additional constraints that necessitate proactive sourcing strategies and scenario-based planning.

To navigate this environment, stakeholders should emphasize integrated planning that links clinical development to manufacturing capabilities and market access strategies. Investment in modular production capacity, supplier diversification, and evidence-generation frameworks will be essential to de-risk development programs and to facilitate adoption across heterogeneous regional markets. Ultimately, organizations that synchronize scientific innovation with operational excellence and strategic foresight will be best positioned to deliver meaningful clinical impact while building sustainable commercial trajectories for cellular immunotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing clinical adoption of CAR-T cell therapies
  • 5.2. Expansion of point-of-care automated cell processing platforms to streamline treatment workflow
  • 5.3. Evolving regulatory frameworks accelerating approval of next-generation gene-edited cellular immunotherapies
  • 5.4. Integration of artificial intelligence and big data analytics optimizing personalized cell therapy manufacturing processes
  • 5.5. Rise of combination therapies pairing CAR-T with checkpoint inhibitors for enhanced efficacy in refractory cancers
  • 5.6. Technological advancements enhancing cell manufacturing efficiency
  • 5.7. Advances in CRISPR-enabled CAR-T cell design drive next-generation immunotherapies
  • 5.8. Strategic partnerships between biotech and pharma drive rapid scale-up of cell therapy manufacturing
  • 5.9. Emerging focus on solid tumor immunotherapy strategies
  • 5.10. Continuous bioreactor innovations boost scalable production yields for next-generation cell therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cellular Immunotherapy Market, by Type

  • 8.1. CAR T-Cell Therapy
  • 8.2. Dendritic Cell Therapy
  • 8.3. NK Cell Therapy
  • 8.4. T-Cell Receptor Therapy
  • 8.5. Tumor-Infiltrating Lymphocytes Therapy

9. Cellular Immunotherapy Market, by Technology Type

  • 9.1. Cytokines & Immunomodulators
  • 9.2. Monoclonal Antibodies

10. Cellular Immunotherapy Market, by Indication

  • 10.1. B-Cell Malignancies
  • 10.2. Liver Cancer
  • 10.3. Prostate Cancer
  • 10.4. Renal Cell Carcinoma

11. Cellular Immunotherapy Market, by Institution Category

  • 11.1. Academic Institutes
  • 11.2. Biotech & Pharmaceutical Companies
  • 11.3. Contract Organizations
  • 11.4. Hospitals
  • 11.5. Research Institutes

12. Cellular Immunotherapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cellular Immunotherapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cellular Immunotherapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Adaptimmune Therapeutics PLC
    • 15.3.2. Adicet Bio, Inc.
    • 15.3.3. Apac Biotech Private Limited
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Atara Biotherapeutics, Inc.
    • 15.3.6. Bellicum Phamaceuticals, Inc.
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. Bristol-Myers Squibb Company
    • 15.3.9. Celyad Oncology SA
    • 15.3.10. Corning Incorporated
    • 15.3.11. Dendreon Pharmaceuticals LLC
    • 15.3.12. Eli Lilly and Company
    • 15.3.13. F. Hoffmann-La Roche AG
    • 15.3.14. Gilead Sciences, Inc.
    • 15.3.15. GlaxoSmithKline PLC
    • 15.3.16. Glycostem Therapeutics B.V.
    • 15.3.17. Immatics N.V.
    • 15.3.18. Inovio Pharmaceuticals, Inc.
    • 15.3.19. Iovance Biotherapeutics, Inc.
    • 15.3.20. Johnson & Johnson Services, Inc.
    • 15.3.21. JW Therapeutics (Shanghai) Co., Ltd.
    • 15.3.22. Lonza Group Ltd.
    • 15.3.23. Merck KGaA
    • 15.3.24. Novartis AG
    • 15.3.25. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 203. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 233. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 240. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 243. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 252. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. ITALY CELLULAR